Investigating how two proteins affect blood vessel formation in a genetic disorder
Official title: UNCOVERING THE COMBINED EFFECTS OF VEGFA AND ANG2 PRO-ANGIOGENIC SIGNALING IN HEREDITARY HEMORRHAGIC TELANGIECTASIA
Funded at Tulane University of Louisiana · NIH-11079432 · Data updated 2026-11-12
This study is looking at how two proteins, VEGFA and ANG2, affect blood vessel problems in people with hereditary hemorrhagic telangiectasia (HHT), with the hope of finding new treatments that could help reduce bleeding and improve daily life for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $48,974 |
| NIH project number | 5F31HL174074-02 |
| Project ID | NIH-11079432 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hereditary hemorrhagic telangiectasia who experience complications from arteriovenous malformations.
✕Less likely to help
Patients without hereditary hemorrhagic telangiectasia or those who do not have complications related to arteriovenous malformations may not benefit from this research.
What this research studies
This research focuses on hereditary hemorrhagic telangiectasia (HHT), a genetic condition that leads to abnormal blood vessel formation and can cause severe bleeding. The study aims to understand how two specific proteins, VEGFA and ANG2, work together to influence blood vessel growth and malformation. By exploring the combined effects of inhibiting these proteins, the research seeks to develop new therapeutic strategies to manage arteriovenous malformations (AVMs) associated with HHT. Patients may benefit from potential new treatments that could reduce bleeding episodes and improve their quality of life.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce bleeding and complications for patients with hereditary hemorrhagic telangiectasia.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting VEGFA and ANG2 in other vascular conditions, suggesting potential for success in this study.
Where this research is happening
-
Tulane University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Bavishi, Shreya — Tulane University of Louisiana
- Study coordinator: Bavishi, Shreya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.